Ton Logtenberg

Ton Logtenberg is the founder and former President and CEO of Merus N.V., a Nasdaq-listed clinical-stage biotechnology company advancing leading-edge, targeted treatments based on multi-specific antibodies to address the unmet needs of cancer patients. Ton was the founder and CEO of U-BiSys, which merged with Introgene to become Crucell, where he served as Chief Scientific Officer responsible for the discovery and development of vaccines and antibodies. Ton co-founded the HUB foundation for organoid technology and served on the board of directors and supervisory board. Recently, Ton co-founded and was appointed CEO of Gyes B.V., a biotech company exploring a next-generation platform for therapeutic multispecific antibodies. He is currently Chairman of the Board of Synox Therapeutics, a Board member of the Forbion European Acquisition Corporation, and a Venture Partner at Forbion. Ton has a Ph.D. in immunology from Utrecht University and did post-doctoral work at Columbia University with Dr. Frederique Alt. Ton was a professor of Immuno-Biotechnology at Utrecht University, where he is currently a professor in Entrepreneurship in the Life Sciences.